Evidence map›Paper›PMID 30216975›Full record

ArticleMolecules (Basel, Switzerland)2018

Selection and Identification of Novel Aptamers Specific for Clenbuterol Based on ssDNA Library Immobilized SELEX and Gold Nanoparticles Biosensor.

Xixia Liu, Qi Lu, Sirui Chen, Fang Wang, Jianjun Hou, Zhenlin Xu, Chen Meng, Tianyuan Hu, Yaoyao Hou

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Preparation and Characterization of Aptamers AgainstInternational journal of molecular sciences · 2020
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xixia LiuHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. liuxixia1@163.com.
Qi LuHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. 18271691835@163.com.
Sirui ChenHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. 17371958850@163.com.
Fang WangHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. WF_0129@163.com.
Jianjun HouHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. jjhou@mail.hzau.edu.cn.
Zhenlin XuGuangdong Provincial Key Laboratory of Food Quality and Safety, South China Agricultural University, Wushan Road, Tianhe District, Guangzhou 510642, China. jallent@163.com.ORCID 0000-0002-1197-4615
Chen MengHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. 13329967633@163.com.
Tianyuan HuHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. 18771808527@sina.cn.
Yaoyao HouHubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Hubei Normal University, Cihu Road, Huangshigang District, Huangshi 435002, China. dxhe@163.com.

Funding

National Natural Science Foundation of China 31601548Open Foundation of Guangdong Provincial Key Labotorary of Food Quality and Safety GPKLFQS201702the Natural Science Foundation of Hubei Province 2016CFB218the Research Fund for Science and Technology Inovation Team of University T201504
6 · The paper itself

Abstract

We describe a multiple combined strategy to discover novel aptamers specific for clenbuterol (CBL). An immobilized ssDNA library was used for the selection of specific aptamers using the systematic evolution of ligands by exponential enrichment (SELEX). Progress was monitored using real-time quantitative PCR (Q-PCR), and the enriched library was sequenced by high-throughput sequencing. Candidate aptamers were picked and preliminarily identified using a gold nanoparticles (AuNPs) biosensor. Bioactive aptamers were characterized for affinity, circular dichroism (CD), specificity and sensitivity. The Q-PCR amplification curve increased and the retention rate was about 1% at the eighth round. Use of the AuNPs biosensor and CD analyses determined that six aptamers had binding activity. Affinity analysis showed that aptamer 47 had the highest affinity (Kd = 42.17 ± 8.98 nM) with no cross reactivity to CBL analogs. Indirect competitive enzyme linked aptamer assay (IC-ELAA) based on a 5'-biotin aptamer 47 indicated the limit of detection (LOD) was 0.18 ± 0.02 ng/L (n = 3), and it was used to detect pork samples with a mean recovery of 83.33⁻97.03%. This is the first report of a universal strategy including library fixation, Q-PCR monitoring, high-throughput sequencing, and AuNPs biosensor identification to select aptamers specific for small molecules.

Indexed as

Adrenergic beta-AgonistsAptamers, NucleotideBiosensing TechniquesCircular DichroismClenbuterolDNA, Single-StrandedGene LibraryGoldHigh-Throughput Nucleotide SequencingLimit of DetectionMetal NanoparticlesSELEX Aptamer TechniqueSequence Analysis, DNAAdrenergic beta-AgonistsAptamers, NucleotideClenbuterolDNA, Single-StrandedGoldaptamersclenbuterolgold nanoparticles biosensorhigh-throughput sequencing technologyreal-time quantitative PCRsystematic evolution of ligands by exponential enrichment

Identifiers

PMID30216975
PMCPMC6225122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.